title: The actions of fentanyl to inhibit drug-induced emesis.
abstract: The ability of fentanyl to inhibit drug-induced emesis was investigated in the ferret. Initial studies established that morphine, in small doses (0.025-0.5 mg/kg s.c.), induced emesis in the ferret that decreased at the larger doses of 1 and 2 mg/kg (s.c.). Fentanyl (10-80 micrograms/kg s.c.) failed to induce emesis but in this dose range prevented the emesis induced by morphine (0.5 mg/kg s.c.), apomorphine (0.25 mg/kg s.c.), copper sulphate (100 mg/kg intragastric) and cisplatin (10 mg/kg i.v.). The antiemetic effects could be obtained in the absence of sedation or motor impairment. The antagonism by fentanyl of apomorphine-, copper sulphate- and cisplatin-induced emesis was inhibited by naloxone (0.1 or 0.5 mg/kg s.c.). It is concluded that fentanyl exerts a broad spectrum of actions to inhibit drug-induced emesis. An autoradiographic study of the binding of [3H]DAGO to the brainstem of the ferret indicated high densities of mu recognition sites in the area postrema, nucleus tractus solitarius, dorsal motor nucleus of the vagus, reticular medulla and other sites. The results are discussed in terms of balanced facilitatory and inhibitory opioid systems, regulating emesis and that the antiemetic actions of fentanyl reflect an important, although not necessarily an exclusive, action at mu opioid receptors.
authors.affiliation: Postgraduate Studies in Pharmacology, School of Pharmacy, University of Bradford, U.K.
authors.forename: N M
authors.initials: NM
authors.lastname: Barnes
authors.forename: K T
authors.initials: KT
authors.lastname: Bunce
authors.forename: R J
authors.initials: RJ
authors.lastname: Naylor
authors.forename: J A
authors.initials: JA
authors.lastname: Rudd
mesh_terms: D000818:Animals; D000932:Antiemetics / Q000008:administration & dosage / Q000494:pharmacology*; D001058:Apomorphine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D001345:Autoradiography; D001933:Brain Stem / Q000033:anatomy & histology / Q000378:metabolism; D002945:Cisplatin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D003300:Copper / Q000037:antagonists & inhibitors / Q000494:pharmacology; D019327:Copper Sulfate; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins / Q000378:metabolism; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D005289:Ferrets; D008297:Male; D009020:Morphine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D011957:Receptors, Opioid / Q000378:metabolism; D017450:Receptors, Opioid, mu; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D004745:Enkephalins; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D009270:Naloxone; D009020:Morphine; D003300:Copper; D019327:Copper Sulfate; D001058:Apomorphine; D002945:Cisplatin; D005283:Fentanyl